Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Seminars in Oncology

• Publication date

  1997-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 9374097
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Synthesis and evaluation of new peptide-linked doxorubicin conjugates as prodrugs activated by prostate-specific antigen

  2020cites this paper
• Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer

  2015cites this paper
• Chemotherapy dose-intensification in breast cancer : is more better?

  2010cites this paper
• Rola biopsji endomiokardialnej w terapii chorób sercowo-naczyniowych

  2008cites this paper
• The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.

  2007cites this paper
• The role of endomyocardial biopsy in the management scientific statement of the ESC (european society of cardiology)

  2007cites this paper
• Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen

  2005cites this paper
• Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.

  2005cites this paper
• A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

  2004cites this paper
• Role of Formulation Vehicles in Taxane Pharmacology

  2001cites this paper
• Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.

  2001cites this paper
• Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium.

  2001cites this paper
• 20th‐Century Advances in Drug Therapy in Oncology—Part I

  2000cites this paper
• Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer

  2000cites this paper
• 20th‐Century Advances in Drug Therapy in Oncology—Part II

  2000cites this paper
• Pharmacologic modulation of taxanes

  2000cites this paper
• A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.

  1999cites this paper
• Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.

  1999cites this paper
• Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.

  1998cites this paper
• Paclitaxelof its Use in the Treatment of Metastatic Breast Cancer and Ovarian and Other Gynaecological Cancers

  1998cites this paper